Page 48 - பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Fewer than 40% of patients with chronic lymphocytic leukemia (CLL) had an adequate immune response to two doses of the Pfizer/BioNTech COVID-19 vaccine, a prospective study showed. Overall, 39.5% of 167 patients with CLL had adequate antibody levels after the second vaccine dose. A matched comparison of a subgroup of patients with CLL and a group of healthy individuals showed that half of the patients with leukemia responded to the vaccine as compared with all of the healthy controls. Vaccine response rates in the patients with CLL ranged from 79.2% for those who had a clinical remission after antileukemic therapy to 16% for patients who were vaccinated during treatment. Patients who had yet to be treated had an antibody response rate of 55.2%, reported Yair Herishanu, MD, of the Tel Aviv Sourasky Medical Center in Israel, and colleagues in

Charles bankheadYair herishanuEvangelos terposTel aviv sourasky medical centerUniversity of pittsburgh medical centerKapodistrian university of athensKapodistrian universityPittsburgh medical centerMedpage todayசார்லஸ் வங்கித் தலைபல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் மருத்துவ மையம்பிட்ஸ்பர்க் மருத்துவ மையம்